Skip to main content

Table 1 US FDA-Approved BCR-ABL1 TKIs

From: Biomarkers for determining the prognosis in chronic myelogenous leukemia

Name

Year approved

Indications in CML

Imatinib

2001

CP, AP, or BC after failure of interferon therapy

2003

Newly diagnosed CP

Dasatinib

2006

CP, AP, or BC after resistance to or intolerance of imatinib

2010

Newly diagnosed CP

Nilotinib

2007

CP or AP after resistance to or intolerance of imatinib

2010

Newly diagnosed CP

Bosutinib

2012

CP, AP, or BC after resistance to or intolerance of prior therapy

Ponatinib

2012

CP, AP, or BC after resistance to or intolerance of prior TKI therapy

  1. AP accelerated phase, BC blast crisis, CML chronic myelogenous leukemia, CP chronic phase, FDA Food and Drug Administration, TKI tyrosine kinase inhibitor, US United States.